

1003 U.S. PTO
04/21/01

11017 U.S. PTO
09/935703
08/24/01

Please type a sign (+) inside this box. + PTO/SB/05 (08-00)

Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR § 1.53(b))

Attorney Docket No.		PT050P1
First Inventor	Shi et al.	
Title	Protein Tyrosine Phosphatase Polynucleotides, Polypeptides, and Antibodies	
Express Mail Label No.		

APPLICATION ELEMENTS
See MPEP chapter 600 concerning utility patent application contents.

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)

2. Applicant claims small entity status.
See 37 CFR 1.27.

3. Specification [Total Pages 269]
(preferred arrangement set forth below)
- Descriptive title of the Invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to sequence listing, a table, or a computer program listing appendix+
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

4. Drawing(s) (35 U.S.C. 113) [Total Sheets 1]

5. Unexecuted Oath or Declaration Total Pages 2
a. Newly executed (original or copy)
b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
i. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).

6. Application Data Sheet. See 37 CFR 1.76.

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
a. Computer Readable Form (CRF)
b. Specification Sequence Listing on:
i. CD-ROM or CD-R (2 copies); or
ii. paper (8 pages)
c. Statements verifying identity of above copies

9. Assignment Papers (cover sheet and document(s))

10. 37 CFR 3.73(b) Statement Power of Attorney

11. English Translation Document (if applicable)

12. Information Disclosure Statement/ Form PTO/SB/08
 Copies of Citations

13. Preliminary Amendment

14. Return Receipt Postcard (MPEP 503)
(should be specifically itemized)

15. Certified copy of Priority Document(s)
(if foreign priority is claimed)

16. Other:

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation Divisional Continuation-in-Part (CIP) of prior application No: PCT/US01/05496

Prior application information: Examiner _____ Group/Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only. The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

18. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label **22195** or Correspondence address below

NAME			
ADDRESS			
CITY	STATE	ZIP CODE	
COUNTRY	TELEPHONE	FAX	
NAME (Print/Type)	Registration No. (Attorney/Agent) 40,302		
SIGNATURE	Date August 24, 2001		

Statement: this form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Box Patent Application, Washington, DC 20231.

FEE TRANSMITTAL
for FY 2001
Complete if Known
Patent fees are subject to annual revision.

Application Number	Unassigned
Filing Date	August 24, 2001
First Named Inventor	Shi et al.
Examiner Name	
Group Art Unit	

 Total amount of payment **(\$746.00)** Attorney Docket Number **PT050P1**
METHOD OF PAYMENT (CHECK ONE)

 1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to:

Deposit Account 08-3425

Number

 Deposit Account **Human Genome Sciences, Inc.**
 Name

 Charge Any Additional Fee Required
 Under 37 CFR §§ 1.16 and 1.17

 Applicant claims small entity status

See 37 CFR 1.27


 2. Payment Enclosed:
 Check Credit Card Money Order Other

Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 08-3425

FEE CALCULATION (CONTINUED)

3. ADDITIONAL FEES		Fee Paid			
Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Code	Fee (\$)
105	130	205	65	Surcharge - late provisional filing fee or cover sheet	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination	
112	920	112	920	Requesting publication of SIR prior to Examiner action	
113	1,840	113	1,840	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive -unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Statement	
581	40	481	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))	
179	710	279	355	Request for Continued Examination (RCE)	
169	190	169	900	Request for expedited examination of a design application	
Other fee (specify): Other fee (specify):					
*Reduced by Basic Filing Fee Paid					
Subtotal (3) \$					

 Subtotal (2) **(\$746.00)** Complete (if applicable)

 Submitted By **Kenley K. Hoover** Registration No.: **40,302** Telephone **301-309-8504**
 Signature:  Date **August 24, 2001**

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Shi et al.

Application Serial No.: Not assigned

Art Unit: Not assigned

Filed: Concurrently herewith

Examiner: Not assigned

For: Protein Tyrosine Phosphatase
Polynucleotides, Polypeptides, and Antibodies

Attorney Docket No.: PT050P1

STATEMENT UNDER 37 C.F.R. 1.821(f)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants hereby certify that the hard copy of the sequence listing being filed concurrently herewith and the enclosed computer-readable form of such sequence listing are identical.

Respectfully submitted,

Date: August 24, 2001


Kenley K. Hoover
Attorney for Applicants

Reg. No. 40,302

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
Telephone: (301) 610-5771

KKH/RL/ur